U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07400744) titled 'A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects' on Feb. 03.
Brief Summary: The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety and immunogenicity profiles of QL2109 and Darzalex following a single intravenous infusion in healthy male subjects.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: QL2109
Recombinant anti-CD38 fully human monoclonal antibody.
DRUG: Darzalex
Daratumumab injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Qilu Pharmaceu...